Nouveau Visage™ launches new 5-in-1 regenerative microneedling system in the UK…
Nouveau Visage™, a French biomedical aesthetics brand announces the UK launch of a new regenerative microneedling system designed for medical aesthetic clinics and dermatology practices. The brand enters the UK market in partnership with Fox Pharma, MedFx, Millenium and John Bannon.
Developed by Laboratoire Nouveau Visage, the system is built around Regen³ Complex, a patented, proprietary technology combining exosomes, PDRN and biomimetic peptides within a single stable microneedling formulation.
Designed to activate multiple regenerative pathways simultaneously, the complex supports cellular communication, fibroblast stimulation and extracellular matrix renewal, positioning the brand within the fast-growing regenerative aesthetics category.
The Nouveau Visage™ portfolio has been developed primarily for medical aesthetic practitioners delivering advanced microneedling treatments. The professional treatment range, known as NEWDERM™, is built around the pillar of ‘one indication, one solution’ - with five targeted protocols addressing key target concerns including:
- NEWDERM™ Age Control, designed to address wrinkles, dehydration and loss of elasticity through deep hydration and stimulation of dermal regeneration
- NEWDERM™ Bright, formulated to target melasma, sun damage and uneven skin tone by limiting melanin synthesis while supporting skin barrier recovery
- NEWDERM™ Eye, developed specifically for the delicate periorbital area to improve dark circles, under eye bags and fine lines while strengthening skin elasticity
- NEWDERM™ Hair, a regenerative scalp treatment designed to support follicle health, improve hair density and revitalise the scalp
- NEWDERM™ Lift, focused on improving skin laxity and dermal structure through collagen stimulation and strengthening of the dermal matrix
All protocols utilise the Regen³ Complex, which combines more than 100 billion exosomes per vial (the highest known concentration) with PDRN and biomimetic peptides. These components work through complementary regenerative pathways to support tissue repair, collagen synthesis and improved skin structure, delivering visible improvements in elasticity, firmness and radiance over a structured course of treatment.
By actively stimulating the skin’s natural repair and regeneration pathways, the Regen³ Complex enhances the effectiveness of every formulation, ensuring faster, more visible, and longer-lasting results .
Carlos Royo, Executive Partner & CEO at Nouveau Visage commented: "The UK aesthetics market continues to move rapidly towards regenerative and biologically driven treatments, and Nouveau Visage™ represents a significant step forward within this space, offering an innovative and versatile treatment portfolio for discerning clinics. We are excited to be launching in the UK and adding this market to our growing list of territories – and we look forward to working closely with aesthetic practitioners, clinics and pharmacy partners to support this exciting rollout."
Dr Apostolos Vlachogiorgos, plastic surgeon and early UK adopter, added: "Regenerative aesthetics is increasingly focused on how we stimulate the skin’s own repair mechanisms rather than simply replacing volume or masking signs of ageing. What makes Nouveau Visage™ particularly interesting from a clinical perspective is the way the Regen³ Complex combines three complementary regenerative technologies within one formulation. In practice, this allows practitioners to achieve improvements in skin texture, elasticity and radiance through a structured treatment course that is both clinically grounded and easy to incorporate into existing microneedling protocols."
The UK launch will be formally introduced to the aesthetic community at a dedicated education and networking event on 12th May at the Bulgari Hotel, London. The event will bring together leading key opinion leaders, clinical educators and industry partners to present the science behind Nouveau Visage™, outline the clinical opportunities for practitioners and explore how clinics can integrate regenerative microneedling treatments into their treatment portfolios.
Attendees will have the opportunity to hear directly from international experts involved in the development of the system, gain deeper insight into the clinical protocols and connect with the Fox Pharma team and brand educators.
Nouveau Visage™ has already launched across more than twenty international markets and is supported by ISO and GMP manufacturing standards, reflecting its positioning as a premium biomedical aesthetics brand grounded in French scientific innovation.
Clinics interested in attending the London launch event or learning more about the Nouveau Visage system can contact Fox Pharma via [email protected].